OPPI releases ‘Healthcare in India: New Milestones New Frontiers’ with McKinsey and Co as knowledge partner
‘Healthcare in India: New Milestones New Frontiers’,
a publication which highlights some existing and future challenges for policy
makers and other stakeholders in healthcare sector, was released by
Organisation of Pharmaceutical Producers of India (OPPI) with McKinsey and
Company as Knowledge Partner recently.
The publication also draws attention to
crucial aspects of the industry and identifies some new priorities bringing
forth five revolutionary themes like using digital data and analytics,
leveraging multi-stakeholder partnerships, upgrading capabilities and raising
the bar of ‘quality of care’ among others.
It was released by Telengana Minister for IT,
Industries and Urban Development Kalvakuntla Taraka Rama Rao (KTR), renewing
OPPI’s commitment to make a difference and strive for a better tomorrow - of
ushering in a “Healthy
India and an Innovative India”.
Releasing the report the Minister said, “Availability, accessibility and
affordability are the three mantras for healthcare. We are working with all the
stakeholders towards realizing vision of healthy India. As the youngest state,
not burdened by legacy, we are forging partnerships with private players and
want to lay emphasis on innovation. I do believe this initiative by OPPI augurs
well for a new state like ours. We are willing to partner with OPPI and work
towards “Healthcare for All”.
The release of the report was followed by a
panel discussion featuring eminent thinkers including Dr Shashi Tharoor, Member
of Parliament - Lok Sabha and Former Minister of State for HRD and External
Affairs, Kalvakuntla Taraka Rama Rao (KTR), Hon’ble Minister for IT,
Industries, Mining, NRI Affairs & Urban Development, Government of
Telangana, Dr C P Thakur, Member of Parliament, Rajya Sabha and Former Union Minister
for Health and Family Welfare, Dr Soumya Swaminathan, Secretary DHR, Ministry
of Health and Family Welfare and Director General ICMR, Dr Shailesh Ayyangar,
President OPPI and Managing Director and Vice President South Asia, Sanofi.
Speaking on the occasion, Dr Shailesh
Ayyangar, President, OPPI said, “Through
this knowledge initiative, we look back at the last 50 years and celebrate the
strides our industry has collectively made. We are aware, of course, that much
remains to be done. Our country has made huge economic progress, but healthcare
outcomes lag expectations. Through this report we also examine the internal and
external challenges that represent a call to action for all stakeholders.
Finally, we lay out a few ideas and choices that could shape the next 50 years.”
The next decade will throw both enormous
challenges and opportunities. OPPI is extremely enthusiastic to work in
coalition with all stakeholders to address the challenges squarely and pick
opportunities to fulfill the dream of ‘Health for all Indians’. OPPI and its
members commit themselves to partner with the Government in many areas,
especially focusing on addressing challenges faced by the primary healthcare
centres, reduce the NCDs burden and increase public awareness on antimicrobial
resistance.
Adding to this, Kanchana TK, Director
General, OPPI said, “Today, conversations
and healthy debates on issues facing our industry and the healthcare system are
critical to addressing some of the current challenges and opportunities of the
future. Global borders are blurring, and
patient-centricity has become the driving force for delivering responsible
healthcare. We are committed to working
with Government and all other stakeholders towards realizing our collective
vision of putting the patient at the centre of all that we do.”
The Organisation of Pharmaceutical Producers
of India was established in 1965 and represents the research-based
pharmaceutical companies in India. OPPI remains committed to supporting the
nation’s healthcare objectives and collaborating with all stakeholders to find
sustainable solutions. OPPI believes the need for innovation must be balanced
with the necessity for more accessible medicines, within a robust IP
environment.
Comments
Post a Comment